Head and Neck Squamous Cell Carcinoma Clinical Trials in Chengdu, Sichuan
9 recruitingChengdu, Sichuan, China
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Breast CancerLung CancerSolid Tumors+1 more
Sichuan Baili Pharmaceutical Co., Ltd.22 enrolled1 locationNCT07274852
Recruiting
Phase 1
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell CarcinomaSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.16 enrolled1 locationNCT07232524
Recruiting
Phase 2
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Head and Neck Squamous Cell CarcinomaTargeted TherapyImmunotherapy+1 more
West China Hospital98 enrolled1 locationNCT07040956
Recruiting
Phase 1Phase 2
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.96 enrolled2 locationsNCT07059221
Recruiting
Phase 2
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Lei Liu90 enrolled1 locationNCT06444009
Recruiting
Phase 3
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Head and Neck Squamous Cell Carcinoma
Akeso510 enrolled2 locationsNCT06601335
Recruiting
Phase 2
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell Carcinoma
Hansoh BioMedical R&D Company170 enrolled25 locationsNCT06007729
Recruiting
Phase 1
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
Head and Neck Squamous Cell Carcinoma
West China Hospital6 enrolled1 locationNCT06109207
Recruiting
Phase 2
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and Neck Squamous Cell Carcinoma
Lyvgen Biopharma Holdings Limited64 enrolled17 locationsNCT06378177